Join the Multiple Myeloma group to help and get support from people like you.
Multiple Myeloma News
Related terms: Cancer, Malignant Plasmacytoma, Cancer, Multiple Myeloma, Cancer, Plasma Cell Dyscrasia, Cancer, Plasma Cell Myeloma, Malignant Plasmacytoma, Myeloma, Multiple, Plasma Cell Dyscrasia, Plasma Cell Myeloma, Plasmacytoma of Bone, Kahler's disease
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
WEDNESDAY, July 16, 2025 – In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets...
FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab-gcpt) for Treatment of Relapsed or Refractory Multiple Myeloma
TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
High-Fiber Plant-Based Diet May Be Beneficial for Monoclonal Gammopathy, Multiple Myeloma
WEDNESDAY, June 4, 2025 – A high-fiber plant-based diet (HFPBD) can be beneficial for patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM),...
Annual Whole-Body, Low-Dose CT Aids Management of Smoldering Multiple Myeloma
TUESDAY, April 22, 2025 – Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), according to a study published online March 25 in...
Black Cancer Death Rate Declining, But Higher Risk Remains
FRIDAY, Feb. 21, 2025 – Cancer deaths among Black men and women in the U.S. have declined during the past decade in the United States, a new American Cancer Society (ACS) report says. The cancer...
Lower Dexamethasone Dose Does Not Impair Survival in Multiple Myeloma
FRIDAY, Jan. 24, 2025 – For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published...
Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma
THURSDAY, Jan. 9, 2025 – For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or...
High-Fiber Diet May Prevent a Blood Cancer in People at High Risk
MONDAY, Dec. 9, 2024 – People who have a condition putting them at high risk for a bone marrow cancer may be able to ward off the malignancy with a high-fiber diet, new research shows. The study...
Genes Highlight Who'll Benefit From Multiple Myeloma Treatment With Venclexta
WEDNESDAY, Dec. 4, 2024 – Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted therapy, a new study finds. A special six-gene pattern can help...
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma
TUESDAY, Oct. 8, 2024 – Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study...
Sarclisa Approved in the US as the First Anti-CD38 Therapy in Combination with Standard-of-Care Treatment for Adult Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
PARIS, September 20, 2024. The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line...
FDA Approves Boruzu (bortezomib) Ready-to-Use Injection for Multiple Myeloma and Mantle Cell Lymphoma
BRIDGEWATER, N.J.--(BUSINESS WIRE) September 5, 2024 – Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) and Shilpa Medicare Limited (“Shilpa”) announced U.S. Food and Drug Adm...
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
THURSDAY, Sept. 12, 2024 – The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study...
Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
HORSHAM, Pa., July 30, 2024 – Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in c...
FDA Approves Carvykti for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
HORSHAM, PA (April 5, 2024) – Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the tr...